WENDY PETERSON: Open Payments
NPI 1841443272 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,540 in 134 payments from 20 companies in 2025. Trend: 2023 $1,925 · 2024 $1,990 · 2025 $2,540
Food & beverage: $2,463Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $506 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $403 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $323 |
| Regeneron Healthcare Solutions, Inc. | 9 | $304 |
| Janssen Biotech, Inc. | 12 | $265 |
| GENZYME CORPORATION | 11 | $148 |
| Madrigal Pharmaceuticals | 1 | $128 |
| Lilly USA, LLC | 5 | $93 |
| Ipsen Biopharmaceuticals, Inc | 4 | $66 |
| Janssen Scientific Affairs, LLC | 1 | $47 |
Products named: DUPIXENT, ENTYVIO, XIFAXAN, RINVOQ, TREMFYA, SKYRIZI, REZDIFFRA, OMVOH.
Industry payments across LA — which companies pay providers there.
